| Objective:Endometrial carcinoma is one of the common gynecological malignancy, In recent years, with the rapid development of testing technology,endometrial carcinoma pathological mechanism has been understood furtherly, Many genetic mutations are the major factors to induce the EC. Exploring the relationship between oncogenes and tumor-suppressor genes of endometrial carcinoma, would look for the New markers for evaluating biological characters and therapy of EC.EZH2(Enhancer of zeste homologue 2)is a critical Polycomb group(PcG) protein homologous to Drosophila Enhancer of Zeste,which is an important member of PcG,plays a critical role in X-inactivation, It is also involved in maintaining the inhibition state of Hox genes ,stem cell pluripotency and cell proliferation. In recent years,accumulating evidences indicate that EZH2 overexpresses in the human cancers maybe promote the proliferation and diffusion of cancerous cells. That suggests EZH2 might become a new tumor markers and the new target of gene therapy, Further uncovers the potential clinical value of EZH2 became many clinical doctors'work hotspot. P53 gene is the most frequent mutational tumor suppressor of human tumor, which is divided into wild type and mutational type. Currently research suggests that the wild type of Activate P53 gene can combine with the promoter of EZH2 gene,and inhibit its expression, So when the wild p53 gene mutations,the inhibition loss might lead to the expression of EZH2 increased,investigating the expression of EZH2 and P53 in normal endometrium, simple hyperplasia, complex hyperplasia, atypical endometrial hyperplasia and endometrial cancer tissue , In endometrial cancer tissues by malignant degree and associated with prognosis divided into two groups:(1)Histological grade: G1+G2 group and G3 group (for the cases of group G1 and Group G2 are less than G3 group ,so take the sum of G1 and G2 to be comparised with G3 );Surgery - pathologic stage: I～II group and III～IV group (for the cases of group III and Group IV are less than I and II group ,so take the sum of III and IV to be comparised with I and II )(.2)The group which muscular layer infiltration depth > 1/2 and infiltration depth≤1/2;The group with the Lymph nodes transfered or not .This study analyzed the difference of expression among two kinds of protein and the relationship between the clinicopathologic characters of endometrial cancer tissue with the protein's expression, as well as the mutual relationship in the development and transfer of the Tumor .The experience would look for the new markers for evaluating gene therapy of endometrial carcinoma tissue.Methods: Randomly selected the surgical resection specimens from The China -Japan Union Hospital of Jilin University and the Centrial Hospital of Changchun from 2008～2010 year in October .All specimens were fresh drawn immediatel after 10% neutral formalin-fixed,paraffin-embedded.Serial sections of 4μm thick, each prepared three different cases, respectively, for HE staining, EZH2 and P53 Immunohistochemical staining reagent positive film box known as a positive control, all the slices were identified by pathology specialists blinded, to detect the expression of EZH2 and P53. All the data using SPSS 17.0 software package, P<0.05 is considered significantly statistic differences.Results:1.EZH2 protein was mainly expressed in the nucleus, the shader of Cells are more apparent, the grad of positive expression rate in 5 to 8 points.The expression rates of EZH2 protein in normal endometrium,simple hyperplasia,complex hyperplasia,atypical endometrial hyperplasia and endometrial cancer tissue is 25.0% , 30.0% , 40.0% , 45.0%,and73.2%. perspectively ,the expression of EZH2 protein in endometrial cancer tissue was significantly higher than that in the normal endometrium, simple hyperplasia, complex hyperplasia and atypical endometrial hyperplasia (χ~2=27.143, χ~2=19.787,χ~2=11.018,χ~2=4.787,P<0.05);while the expression of EZH2 in normal endometrium,simple hyperplasia, complex hyperplasia and atypical endometrial hyperplasia has no statistically significant (χ~2=2.198,P>0.05). In endometrial adenocarcinoma, the expression of EZH2 was closely related with the degree of Pathology classification .The positive expression rate in pathological grade 3 cases was higher than those in grade 1 and grade 2 cases(χ~2=5.963,P<0.05). In the clinical pathologic stage , the positive expression rate of EZH2 in III~IV group is higher than I~II group (χ~2=4.470,P<0.05) . There is statistically significant difference. The positive expression rate in deep muscular layer invasion >1/2 cases was higher than deep muscular layer invasion≦1/2 cases(χ~2=4.371,P<0.05). while the expression of EZH2 was independent of lymphatic metastasis (χ~2=0.251,P>0.05).2. P53 protein was mainly expressed in the nucleus, the shader of Cells are not apparent than that of EZH2, the grad of positive expression rate in 4 to 6 points.The expression rates of mutant p53 protein in normal endometrium, simple hyperplasia, complex hyperplasia, atypical endometrial hyperplasia and endometrial cancer tissue is 0.0% , 10.0% , 15.0% , 45.0%,and71.4%. perspectively ,the expression of P53 protein in endometrial cancer tissue was significantly higher than that in the normal endometrium, simple hyperplasia, complex hyperplasia and atypical endometrial hyperplasia (χ~2=30.159,χ~2=22.493,χ~2=19.101,χ~2=4.494,P<0.05); The expression of P53 protein in atypical endometrial hyperplasia tissue was significantly higher than that in the normal endometrium,simple hyperplasia,complex hyperplasia.(χ~2=9.176,χ~2=6.144,χ~2=4.286,P<0.05).In endometrial adenocarcinoma, (1) Associated with malignant degree:The expression of P53 was closely related with the degree of Pathology classification .The positive expression rate in pathological grade 3 cases was higher than those in grade 1 and grade 2 cases(χ~2=4.487,P <0.05). In the clinical pathologic stage , the positive expression rate of P53 in III~IV group is higher than I ~II group (χ~2=5.258,P<0.05) . There is statistically significant difference. (2)Associated with outcome:The positive expression rate in deep muscular layer invasion >1/2 cases was higher than deep muscular layer invasion≦1/2 cases(χ~2=5.316,P<0.05). while the expression of P53 was independent of lymphatic metastasis (χ~2=0.100,P>0.05).3.Statistical results show that there is correlation between the expression of EZH2 and P53 protein in endometrial carcinoma tissues(r=0.064,P<0.05). Conclusion: 1. The expression of EZH2 in the endometrial carcinoma tissue is significantly higher than that of other groups.wich prompted that the genes of EZH2 could promote the occurrence and development of the endometrial cancer .The detection of EZH2 might be helpful to identify the benign and malignant of EC.2.The expression of mutanted P53 in the endometrial carcinoma tissue is significantly higher than that of other groups,wich prompted that the genes of the mutanted p53 could promote the occurrence and development of EC.The detection of p53 might be helpful to identify the benign and malignant of the endometrial carcinoma 3.In endometrial adenocarcinoma, the expressions of EZH2 was significantly higher in the G3 degree of Pathology classification,the later clinical pathologic stage and the deep muscular layer invasion≦ 1/2 cases. The high expression of EZH2 in EC might herald a high degree of malignant tumor with a poor prognosis.4.In endometrial adenocarcinoma, the expressions of mutanted P53 was significantly higher in the G3 degree of Pathology classification,the later clinical pathologic stage and the deep muscular layer invasion≦ 1/2 cases.The high expression of mutanted P53 in EC might herald a high degree of malignant tumor with a poor prognosis.5.EZH2 and P53 gene are likely to have synergy effect to some extent during carcinogenesis and development of endometrial carcinoma. It support that United detection of EZH2 and P53 in EC may conquer the weakness of indicate that the sensitivity and the lower accuracy of single detection,it may be helpful to the Reaction to the occurrence and development of tumor more reliable,and also helpful to the diagnosis,treatment and evaluating the prognosis of EC. |
PDF Full Text Request